---
title: "Sinobioway Medicine: The company is at risk of triggering other risk warnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247163499.md"
description: "Sinobioway Medicine announced that its holding subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., may trigger other risk warnings due to the suspension of production and sales. According to the relevant regulations of the Shenzhen Stock Exchange, if the company's production and operation are severely affected and it is expected to be unable to resume normal operations within three months, risk warnings will be implemented. This event has a significant impact on the production and operation of Sinobioway Medicine"
datetime: "2025-07-03T13:06:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247163499.md)
  - [en](https://longbridge.com/en/news/247163499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247163499.md)
---

# Sinobioway Medicine: The company is at risk of triggering other risk warnings

According to the Zhitong Finance APP, Sinobioway Medicine (002581.SZ) announced a stock price fluctuation, stating that its controlling subsidiary Tianjin Sinobioway Biomedical Co., Ltd. (referred to as "Tianjin Sinobioway") was subjected to risk control measures of suspending production and sales on April 22, 2025. According to Article 9.8.1 (5) of the "Shenzhen Stock Exchange Stock Listing Rules" (2025 revision): If the company's production and operation activities are severely affected and are expected to not return to normal within three months, the company's stock will be subject to other risk warnings. Tianjin Sinobioway is an important subsidiary of the company, and the aforementioned event has a significant impact on the company's production and operations. If Tianjin Sinobioway is expected to be unable to resume production within three months, the company may trigger other risk warnings

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)

## Related News & Research

- [Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial](https://longbridge.com/en/news/287276752.md)
- [14:47 ET6th Annual Midwest Design Awards Entry Period Now Open](https://longbridge.com/en/news/286808240.md)
- [BRIEF-Mexico's Fibra Next Extends, Raises Public Offer For Fibra Macquarie](https://longbridge.com/en/news/287128862.md)
- [858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting](https://longbridge.com/en/news/287275117.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)